Skip to content
Pharmacology intermediate

Glucose-Dependent Insulinotropic Polypeptide

GIP is an incretin hormone that enhances glucose-stimulated insulin secretion and forms the basis of dual agonist therapies alongside GLP-1 receptor activation.

By Wikipept Community | 3 min read
GIPincretininsulindual-agoniststype-2-diabetesobesity

Glucose-Dependent Insulinotropic Polypeptide

Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid peptide hormone belonging to the secretin family. Originally discovered as a gastrointestinal inhibitor of gastric acid secretion, GIP was later identified as a major incretin hormone that potentiates insulin release following oral glucose intake.

Discovery and Nomenclature

GIP was first isolated from porcine duodenal extracts in 1970. The original name reflected its gastric inhibitory function, but as its insulinotropic properties became apparent, the name was revised to glucose-dependent insulinotropic polypeptide. The glucose-dependent aspect is critical: GIP stimulates insulin secretion only when blood glucose levels are elevated, providing a natural safety mechanism against hypoglycemia.

Structure and Receptor

GIP is synthesized as a 153-amino acid preprohormone in enteroendocrine K-cells, primarily located in the duodenum and jejunum. Proteolytic processing yields the mature 42-amino acid peptide. The N-terminal 13 amino acids are essential for receptor binding and biological activity.

The GIP receptor (GIPR) is a class B G-protein coupled receptor expressed on pancreatic beta cells, adipocytes, osteoblasts, and in the central nervous system. Activation stimulates adenylyl cyclase, increasing intracellular cAMP and activating protein kinase A.

Incretin Effect

The incretin effect accounts for 50-70 percent of postprandial insulin secretion. Oral glucose produces significantly greater insulin response than equivalent intravenous glucose, despite achieving identical plasma glucose levels. GIP and GLP-1 are the two primary incretin hormones.

In type 2 diabetes, the incretin effect is diminished. GIP responsiveness is impaired in many patients, while GLP-1 responses are often preserved. This differential impairment has influenced therapeutic development strategies.

Biological Actions

GIP exerts multiple physiological effects:

Pancreatic Effects

  • Enhances glucose-stimulated insulin secretion
  • Promotes beta cell proliferation and survival
  • Stimulates glucagon secretion (though this effect is glucose-dependent)

Adipose Tissue Effects

  • Promotes lipid storage and adipocyte differentiation
  • Stimulates lipoprotein lipase activity
  • Enhances fatty acid uptake

Bone Metabolism

  • Promotes osteoblast activity and bone formation
  • May protect against bone resorption

Central Nervous System

  • Regulates appetite and energy homeostasis
  • Modulates hippocampal synaptic plasticity

GIP-Based Dual Agonists

The most significant therapeutic advance involves dual GIP/GLP-1 receptor agonists. Tirzepatide (Mounjaro) was the first approved dual agonist, combining GIP and GLP-1 receptor activity in a single 39-amino acid peptide.

Tirzepatide incorporates several design innovations:

  • A C-20 fatty acid for albumin binding and extended half-life
  • D-amino acid substitution at position 2 for DPP-4 resistance
  • Modified sequence optimizing both receptor activities

Clinical results demonstrate superior glycemic control and weight loss compared to selective GLP-1 agonists. Tirzepatide achieved HbA1c reductions exceeding 2 percent and weight loss up to 20 percent in some trials.

Therapeutic Implications

GIP-based therapies extend beyond diabetes and obesity:

  • Metabolic syndrome: Addressing multiple metabolic pathways simultaneously
  • NASH/NAFLD: Potential hepatic benefits through combined incretin actions
  • Cardiovascular risk: Ongoing studies evaluate cardioprotective effects
  • Neurodegenerative disease: GIP receptor agonism shows neuroprotective properties in preclinical models

Mnemonic: GIP GLUCOSE

Remember GIP functions with GIP GLUCOSE:

  • Gastric acid inhibition (original function)

  • Insulin potentiation (incretin effect)

  • Pancreatic beta cell survival

  • Glucose-dependent action

  • Lipid storage in adipose tissue

  • Uptake of fatty acids

  • CAMP signaling via GIPR

  • Osteoblast stimulation in bone

  • Synaptic plasticity in brain

  • Energy homeostasis regulation

Future Directions

Understanding GIP physiology continues to reveal therapeutic opportunities. Next-generation dual and triple agonists combining GIP with GLP-1 and glucagon receptor activities represent the frontier of metabolic disease treatment.